Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial.

[1]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[2]  E. Topol,et al.  Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. , 2003, Journal of the American College of Cardiology.

[3]  M. Mcclellan,et al.  Cardiac Procedure Use and Outcomes in Elderly Patients with Acute Myocardial Infarction in the United States and Quebec, Canada, 1988 to 1994 , 2003, Medical care.

[4]  D. Baim,et al.  Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. , 2002, Journal of the American College of Cardiology.

[5]  A. Kastrati,et al.  Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. , 2002, Journal of the American College of Cardiology.

[6]  B. Davis,et al.  Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial , 2002, Circulation.

[7]  R. Califf,et al.  Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. , 2002, JAMA.

[8]  P. Serruys,et al.  Clinical and Angiographic Factors Associated With Asymptomatic Restenosis After Percutaneous Coronary Intervention , 2001, Circulation.

[9]  C. Morillo,et al.  Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. , 2001, Journal of the American College of Cardiology.

[10]  J. Popma,et al.  Impact of Smoking on Clinical and Angiographic Restenosis After Percutaneous Coronary Intervention: Another Smoker’s Paradox? , 2001, Circulation.

[11]  N. Danchin,et al.  Increased C-reactive protein levels in patients with in-stent restenosis and its implications. , 2001, The American journal of cardiology.

[12]  F Unger,et al.  Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. , 2001, The New England journal of medicine.

[13]  J. Tanguay,et al.  Platelets and restenosis. , 2000, Journal of the American College of Cardiology.

[14]  H. Miller,et al.  High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. , 1998, The American journal of cardiology.

[15]  M. Hadamitzky,et al.  Predictive factors of restenosis after coronary stent placement. , 1997, Journal of the American College of Cardiology.

[16]  V. Burke,et al.  Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty. , 1995, Circulation.

[17]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[18]  M. Hlatky,et al.  Differences in the treatment of myocardial infarction in the United States and Canada. A comparison of two university hospitals. , 1994, Archives of internal medicine.

[19]  Charles L. Brown,et al.  Can restenosis after coronary angioplasty be predicted from clinical variables? , 1993, Journal of the American College of Cardiology.

[20]  S. Goldberg,et al.  Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty--a report from the M-HEART Group. , 1990, The American journal of cardiology.